http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
연구논문 : 만성 B형간염 환자에서 엔테카비어 투여 후 발생한 유전자형 내성
김병욱 ( Byeong Uk Kim ),구자충 ( Ja Chung Goo ),박병출 ( Byeong Chul Park ),김수옥 ( Soo Ok Kim ),홍선표 ( Sun Pyo Hong ),정지인 ( Jee In Jeong ),채희복 ( Hee Bok Chae ),박선미 ( Seon Mee Park ),윤세진 ( Sei Jin Youn ) 대한간학회 2010 Clinical and Molecular Hepatology(대한간학회지) Vol.16 No.2
Background/Aims: The prevalence and clinical characteristics of entecavir (ETV) resistance is not well known. The aim of this study was to determine the frequency of genotypic resistance in nonresponders and virologic breakthrough (VBT) patients. Methods: The medical records of 76 chronic hepatitis B patients treated for a least 6 months from October 2006 to October 2008 were reviewed retrospectively. We divided patients into two groups: nucleoside analogue (NA)-na?ve patients (n=38) and lAM experienced patients (n=38). NA-na?ve and lAM experienced patients received ETV at 0.5 and 1.0 mg/day, respectively. The virologic response and VBT were investigated in both groups. We used the multiplex restriction fragment mass polymorphism (RFMP) method to test genotypic resistance at the rtI169, rtT184, rtS202, rtM204, and rtM250 sites. Results: Age, gender, serum AlT, and HBV DNA level before treatment did not differ between the groups. Neither VBT nor nonresponse was observed in the NA-na?ve group, whereas VBT and nonresponse were observed in three patients each in the lamivudine (lAM)-experienced group, all six patients had YMDD mutation at study enrollment, all three patients with VBT had genotypic resistance to ETV, but the three nonresponse patients did not have genotypic resistance to ETV. Conclusions: We suspect that VBT is mostly associated with genotypic resistance to ETV. However, nonresponse might be associated with the continuance or reselection of the YMDD mutant in lAM-experienced patients.